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Pharmacokinetic equations describing the course of bodyfluid concen- 
trations have been succesfully applied for the design of dosage regimens 
in e.g. chemotherapy (K rüger T hïemer & B ünger 1965 & 1966; D oluï- 
sio  & D ittert 1969) and cardiology (Jelliffe 1967). They are based on 
the assumption of a relatively simple relationship between the concentra- 
tion in the bodyfluid where the drug can be assayed and the concentration 
in a closely related bodyregion, which is responsible for the pharmacological 
activity, but where it cannot be sampled. In the case of chemotherapy 
defined criteria for activity can be used both in vivo  and in vitro. Since 
the clinical criteria for many drugs are vague and subjective, there is a 
great need for more objective parameters that can be used in accompaning 
the patients drug treatment. In many cases the kinetic parameters for the 
use of the regimen calculation are estimated from data after a single dose. 
However, many individual factors mediate the response and the availibility 
of the drugs in the bodyfluids.
This paper deals with the single dose, steady state and post steady state 
kinetics of diazepam and its primary metabolite desmethyldiazepam. Spec- 
ific and general factors will be discussed that can explain the individual 
and species differences in pharmacokinetics.
Methods
Gas chromatographic analyses in plasma of humans and dogs.
Diazepam (valium®, abbreviated:D) and its metabolites: desmethyldiazepam (DD), 
oxydiazepam (OD) and oxydesmethyldiazepam (or oxazepam; serax®) (O) can simul- 
taneously and specifically be assayed in bodyfluids at the pharmacological levels using 
a gas chromatographic method and ®3Ni-electroncapture detection (M a rcu c c i et al, 
1968; v a n  d e r  K le ijn ,  1969c).
'The minimum level that can quantitatively be assayed is 30 ng/ml using N-benzyl-5- 
chlor-2-aminobenzophenon, medazepam or griseofulvin as intemal Standard.
Isotope dilution analyses in dogs.
D was administered intravenously in dogs in a dose of 1 mg/kg corresponding to 2 |xci / 
kg. In one experiment diazepam labeled with UC  in the CVposition, in a second experi­
ment diazepam labeled in the Ni-CHa-position, was used. Heparinized samples of 20 ml 
were frequently taken at increasing intervals from a catheter placed in the femoral 
artery.
1.0  ml plasma was used for total radioactivity measurement by liquid scintillation 
counting (Packard, Model 3380 AAA).
2.0 ml plasma were used for the gas chromatographic analysis of parent diazepam 
and metabolite (DD). 11 ml of the sample were used for the determination of plasma 
protein free fraction of total radioactivity.
Autoradiography in mice.
Distribution of the radioactive drug was studied by means of the whole body auto- 
radiographic method of U l l b e r g  (1954) using a Jung-K microtome (v a n  d e r  K le ijn  
1969c). In this study diazepam-Ni-l^CHg was used. The specific activity of the com- 
pound amounted to 25.7 mg/mci.
200 (xci 5.1 mg/kg was administered intravenously in the tail vein. The drug was 
solubilized in a saline solution containing 2  % polysorbate 80.
Studies in humans.
The test subjects were psychiatrie patients, who had been exposed to several drugs 
during their chronic hospitalization. They were examined physically and found healthy. 
For the sake of this study other drugs were withheld during at least one week prior to 
the diazepam treatment.
The drug was administered as the commercially available 10 mg tablets at equal 
intervals of 8 hrs during 15 subsequent days. After this period the drug and metabolite 
concentrations were followed during the next 4 days.
One patiënt here reported received a single dose of 30 mg 24 hrs before the sub- 
chronic study, that lasted 13 days and subsequent 3 days.
Samples were taken at increasing intervals after the single dose, and during the post 
treatment period. During the subchronic study samples were taken 1 hour after the 
intake of each dose during the first three days and 1 hour after the last dose on the 
subsequent days.
Plasma protein binding.
The plasma protein binding capacity has been determined with the preparative ultra- 
centrifugatión method as earlier reported (v a n  d e r  K le u n  1969) at 70,000 rpm.
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Results
Dogs.
The experiment in dogs are undertaken to enable a more accurate 
analysis of the kinetic pattem of diazepam in plasma than is technically 
feasible in humans.
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Fig. 1. Concentration-time course of total radioactivity in bloodplasma (*“*), of total 
radioactivity in plasma water (•-•), of diazepam (O -O ) and desmethyldiazepam 
( □ - □ )  after rapid intravenous administration of 1  mg diazepam/kg in two dogs.
In fig. 1 it is shown that the elimination of the parent diazepam occurs 
along at least a triphasic curve. In general the accuracy of the kinetic 
parameters as they can be derived from concentration-time curves after a 
single dose depends largely on the accuracy of the last phase of the 
curve (Wagner 1969).
Unfortunately it is not possible to determine the drug long enough during 
this last phase. It can be remarked that using the 14C2-labeled compound 
a shoulder in the curve of the total radioactivity is observed. This is even 
more pronounced for the total radioactivity in the plasma water.
After the first three hours the protein binding capacity hardly changes 
anymore, indicating that metabolism has resulted in one or more compounds 
that show a protein binding capacity of about 58 %.
After administration of the N-14CHg-labeled compound the elimination 
pattem of the total radioactivity is different. The protein binding capacity 
increases during the time course.
Mice.
Macroautoradiography is a useful techniqueto studythe actual significance 
of the plasma concentration for the distribution of the drug in the body. 
It allows a visual localization of the drug in regions where it cannot be 
detected by sampling techniques. Plasma may poorly reflect the kinetic 
processes relevant for the pharmacological activity or for distribution of 
drugs with selective tissue partioning or binding.
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Earlier studies (van der  K leijn 1969a) using 14C2-labeled diazepam 
demonstrated that although the parent drug is rapidly eliminated, the 
metabolites aire long retained in the body, e.g. in the gastrointestinal tract, 
the liver and the white matter of the spinal cord and the brain. By using 
the Ni-14CHs-labeled compound it can be confirmed that the parent drug 
is very rapidly eliminated. No significant excretion of radioactive material 
into the stomach can be observed in the presented autoradiograms. At 
short periods after injection a rapid uptake in the adipose tissue is evident. 
The elimination from the brain proceeds faster than from the bodyfat. The 
initial uptake in the spinal cord, the gray matter of diencephalon, and 
cortex is similar to other ataractic drugs. No long retention of material in 
the white matter can be observed in these mice.
A  small amount of radioactive material is excreted into the gall bladder 
and subsequently into the intestine. The drug shows an initial high affinity 
for the myocardium. After 1 hour virtually no drug can be observed in 
tissues other than the excretory organs.
Remarkable is the uptake in bone marrow, salivary glands, lachrymal 
glands and the skin that can be observed even after 18 hrs following 
the administration (figs. 2 and 3). The pattems after 4 hrs and later resemble 
the distribution of radioactivity following the injection of radioactive formal­
dehyde (H e spe  & P rins , personal communication 1969).
Studies in humans.
In earlier studies (de  Silva et al. 1966; van der  K leijn 1969c) it was 
observed that after a single oral dose of diazepam it was not possible to 
estimate the individual kinetic parameters because of the erratic course of 
the concentration.
After an initial rapid absorption phase and subsequent rapid decline, a 
recovery of the level was observed followed by a much slower elimination 
part. This latter phase, with a half-life longer than the dosage interval, is 
responsible for accumulation during chronic treatment under the condi- 
tions that there are no changes in distribution volume or metabolic capacity. 
The analytical minimum concentration that could be assayed also did not 
allow a conclusion regarding the metabolite after one dose.
The observed rise in plasma level was correlated with food intake and 
will be discussed later. Fig. 4 gives an example of a patiënt where this re­
covery of the concentration has not been observed initially and a biphasic 
elimination curve can be shown after a single dose of 30 mg diazepam. 
During the subchronic treatment of 3 doses of 10 mg daily, accumulation 
of both diazepam (D) and desmethyldiazepam (DD) takes place, D reaching 
a steady state after approximately 4 days and DD reaching it after about 
5 days. After the treatment has been stopped both the D and the DD concen-
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Fig. 2. Autoradiograms of diazepam-N-UCHg in mice during the first 10 min. after 
rapid intravenous administration of 5.1 mg/kg. White areas correspond to presence 
of radioactivity. Notice the rapid disappearance of the radioactivity from the body 
as compared with earlier autoradiograms using diazepam-MCg (v a n  d e r  Kleijn 1969).
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Fig. 3. Autoradiograms of diazepam-N-i4CH3 in mice during the period of 20 min.- 
18 hrs after rapid intravenous administration.
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Fig. 4. Blood plasma concentration-time course of diazepam (D) and its metabolite 
desmethyldiazepam (DD) in a psychiatrie patiënt after a single dose of 30 mg, during 
subchronic treatment with 3 times 10 mg daily during 13 days and during subsequent 
3 days following the treatment. Notice that the initial elimination pattern differs 
from the post treatment pattern (patiënt dB).
tration show an erratic time course (fig. 5). The earlier shown rapid initial 
decay is no longer observed anymore. This can theoretically be expected 
as will presently be discussed. Within certain limitations a half-life of 
24 hrs for D can be estimated in patiënt d B.
The concentration time curves represented in fig. 6 show the accumula-
h
Fig. 5. Rescaled blood plasma concentration-time course of D and DD during the 
post subchronic treatment period presented in fig. 4. Notice that during the initial 
decay an erratic course is shown of both D and DD.
116 E. VAN DER KLEIJN et al.
Fig. 6 . Plasma concentration-time course of D and DD in four psychiatrie patients 
during subchronic treatment with 3 times 10 mg D daily over 15 days and the 
subsequent 4 days following the treatment.
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Fig. 7. Rescaled blood plasma concentration-time course of D and DD during the 
post treatment period in the four patients represented in fig. 6 .
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Table 1.
Cpi =  average blood plasma concentration at the steady state plateau level (mg/1).
Subscriptions D and DD =  diazepam and desmethyldiazepam
t |  =  biological half-life (hr)
kig =  rate of elimination of diazepam (hr'i)
kg3 =  rate of elimination of desmethyldiazepam (hr"i)
M Clearance =  metabolic clearance; the volume of the apparent steady-state volume of 








dB 10 8 1.50 0.40 24 48 95
S 10 8 0.80 0.43 24 56 68
J 10 8 0.85 0.35 20 42 60
v T 10 8 0.70 0.52 30 44 80
V 10 8 1.30 0.46 42 96 78.5







dB 28.8 X 10-3 14.1 X 10-3 108.0 X 10-3 6.4 0.833 28.9 30
S 28.8 X 10-3 12.3 X 10-3 53.6 X 10-3 12.9 1.563 54.3 77
J 34.7 X 10-3 16.5 X 10-3 84.3 X 10-3 8.2 1.471 42.4 77
v T 23.1 X 10-3 15.7 X 10-3 31.1 X 10-3 22.3 1.786 77.3 96.5
V 16.4 X 10-3 7.2 X 10-3 46.3 X 10-3 15.0 0.962 58.7 74
V =  apparent volume of distribution at the steady-state (1).
A  BW =  fraction of bodyweight taken by V.
* This value has been determined from the tangent of the post treatment curve. 
** This value has been determined with the aid of eq. 12.
tion pattems of D and DD during subchronic treatment with 3 divided 
doses of 10 mg daily and the post treatment course. In fig. 7 the time 
basis is rescaled allowing a better picture of the elimination pattern. The 
pharmacokinetic parameters that can be obtained from this post treatment 
curve also suffer from inaccuracy. An estimate of the biological half-life 
of the drug in humans is made in table 1. Estimation of the half-life of 
DD that has qualitatively a similar but quantitatively a slightly lower phar- 
macological activity (Randall et al. 1965) has theoretical and practical im- 
plications that will be described in the discussion.
Plasma protein binding of D has been determined to be virtually linear 
over the therapeutic concentration range (fig. 8).
A protein binding capacity of 96 % has been calculated.
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Fig. 8. Blood plasma protein binding capacity of diazepam in human plasma,
at 70,000 rpm.
Discussion
There are two basic questions that have to be considered for every 
drug and individual before one can depend on pharmacokinetic parameters 
calculated from plasma concentrations to predict or correct dosage regi- 
mens.
First, what is the relation between the concentration in the body fluid 
where the drug can be assayed and the concentration in the organ, tissue 
or humour where the drug will demonstrate its activity? Second, what is the 
relevance of a peripheral or regional concentration for the nature and 
intensity of the action?
The first question may be answered by the use of mathematical models 
commonly used in pharmacokinetics. The principle on which pharmaco- 
kinetics operate is that the relationship between the concentration of the 
drug in one body and the concentration in one or more peripheral body- 
fluids can be expressed in mathematical terms. In many cases an excellent 
fit of data has been obtained assuming one, two or three mathematical 
compartments and first order mass transfer. To extend the meaning of 
these abstract compartments there is a tendency to identify them with 
anatomical or physiological regions and spaces. This appears only to be 
valid in a restricted number of compounds e.g. iodine albumine, inuline, 
antipyrine etc.
The value of this approach largely depends on the accuracy, the spec- 
ificity of the assay, the connected detection range and the sampling pro­
tocol. These factors will determine, whether or not the different com­
partments can be distinguished.
For many drugs the hypothetical peripheral compartments may indeed 
show the postulated homogeneity.
However, many other drugs show selective tissue affinity, that mathe- 
matically moreover will often be of a non-linear type. In humans it is 
practically impossible to estimate a peripheral drug concentration and
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much of our knowledge is based on animal experiments. But here too, 
technical improvements have to be made in order to detect these relations 
between the plasma and the receptor or “molecular” level.
Because of the anticipated difficulties after a single dose where distribu­
tion, elimination with linear and non-linear kinetics can complicate the 
patterns in the different compartments, it is often more simple to study 
the plasma concentration-pharmacological activity relationship at the steady 
state level of the drug. However it can be very difficult to establish the 
same clear multi steady state level-pharmacological response relationship 
as have succesfully been found in isolated organ experiments (Ariëns et al. 
1964).
When biological half-life and dosage interval allow only negligible con­
centration fluctuations and when absorption is relatively rapid and complete,
Fig. 9, insertion. Schematic representation of a catenary chain system with zero order 
infusion (k0) into compartment 1. The rate constants representing the mass transfer 
between the compartments are considered to be of the first order type. The drug 
as well as the metabolites 2 and 3 are supposed to be distributed in one compartment. 
Fig. 9. Theoretical amount-time curves after a single dose of drug, of its metabolite, 
during linear infusion and following the infusion period. For the sake of a clear 
illustration the elimination of the drug is 2  times faster than of the metabolite, this 
in contrast with most of the observations with D and DD in humans. k0 =  0.45 unit 
weight/time; ki2 =  0.9 time~i; kgj =  0.45 time'l. Qi and Q2 are the amounts of drug 
and of metabolite after a single dose of Q =  0.45 unit weight. The subscriptions A 
and B indicate the infusion — and the post infusion period respectively. When both 
drug and metabolite are pharmacologically active, then the elimination of the active 
moiety is slower than of the parent compound even when the metabolite is eliminated
more rapidly.
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then apparent linear zero order infusion kinetics can be applied to describe 
the accumulation of the drug and metabolites in plasma.
The theoretical aspects of linear infusion have recently been reviewed 
by Gibaldi (1969) and in a more general form by Loo &  Riegelman 
(1970). From their work it becomes clear that since accumulation takes 
place it will technically be easier to decide on the kinetic characteristics 
of a drug. It also explains that when there are relatively large differences 
between the rate constants in e.g. a two compartment model it becomes 
more difficult to distinguish the two phases of the post infusion plasma 
curves as the time of infusion is increased.
This can also explain the change in half-life of tetracyclines (D oluisio &  
D titert 1969) during subchronic treatment where an initially unobserved 
slower elimination phase may control the post steady state curve. This 
explanation is also valid for the difference in apparent elimination rate 
of diazepam after a single dose and after subchronic treatment (fig. 4).
The concentration pattern as reported in fig. 6 may be treated in a simple 
catenary chain system for the precursor-product relationship, according to 
the insertion in fig. 9, assuming a one compartment model (1) for the 
drug (D) with zero order infusion with rate k0 (mg/hr) and one com­
partment (2) for the metabolite (DD).
In the case of diazepam both the parent compound D  and DD are 
completely eliminated by metabolism since no intact material has been 
found in urine or faeces.
The mathematical equations have been derived by R esigno  &  Segre 
(1966) and W agner (1969).
Q ja =  (ko/k is) • (1 -  ff*»»)
Q2a =  (ko/kflO • [1 +  -  k12e -^ ‘)/(k1s -  k®)] (2)
Q®a =  k0(kis — k23+  l)/(kig — kg3)
[(kis/k23)e 'k2»t -  (kg3/i2)e 'ki2‘] (3)
When the linear infusion is stopped at time t =  t1 and the quantity of the 
drug if followed during time t — t1 =  t11 then the following set of equations
apply:
QiB =  (ko/W  • (1 -  e r W ) • e-ki*‘n (4)
Q2b =  (ko/k is) • (1  -  r W 1) • [k 12/(k33 -  k i2) ] ' (e 'kiat“ -  Q~k^ n)  +
(ko/kas) • [1 +  l/(ki2 -  kss) f e e - ^ 1 -  kiae-*»4*)] ' e ^ 11 (5)
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CFb — kg3  ^ i Q2B dt (6)
When the infusion time t1 is great, then equations 4 and 5 can be simplified to 
Q*b =  (k0/kig)e'ki2tn (7)
C F b  =  (k o /k g g ) +  [ k 0/(k23  -  k ls ) ] ( e - k 12t“  _  e -k 23t » )  ( 8 )
Since the amount excreted (Q3) has not been assayed in this study it will not 
be considered further.
A tt11 =  0:
Q ‘b =  k0/ki2 (9)
and
O^ b =  k0/kg3 (10)
In these equations Q is quantity of the drag, the superscriptions 1, 2 and 3 
refer to the compartments. Subscriptions A and B refer to the infusion and 
post infusion period respectively, k stands for the first order rate constant 
(hrs-1), the subscriptions indicate the direction of the mass transfer, and t is 
the time after starting the infusion. Also
Q -  C.V. (11)
where C is the concentration and V is the apparent distribution volume 
at the steady-state.
When we, with all reserves, assume the same distribution volume for Qi 
and Qa then k23 can be calculated from the ratio of the steady-state plasma 
concentrations, when kig is determined from the post treatment curve.
C1 _  ka _  tlD
C2 kls t iDD { )
The assumption of equal volumes for parent compound and metabolite is 
arbitrary. Only studies under equal conditions with the metabolite given as 
parent compound can solve this problem.
The post treatment or post infusion curve of the drug does not allow an 
accurate estimate of the rate of elimination of the metabolite. The course of 
the curve of the metabolite (2) is determined by two terms (eq.8). The second 
part approaches more rapid to zero than the first part of the rightliand side 
of the equation. So theoretically only the tangent to the curve will give the k23 
value (fig. 9).
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A  large discrepancy can be noted between the value of k23 calculated from 
the steady-state concentrations and that determined from the tangent of the 
post treatment curve (table 1). Desmethyldiazepam has qualitatively a similar 
but quantitatively a slightly lower pharmacological activity in animals (Ran- 
dall et al. 1965; M arcucci et al. 1968). If this can be translated to man then 
it is not the intrinsic elimination rate of D D  (k23) but the more complex 
function (eq.8) that has to be considered in the additive relation with the 
pharmacological activity.
The catenary infusion model serves as a simplified scheme for the chronic 
treatment of drugs in humans. A  two or more compartment model for the 
drug may be masked by the long treatment and the erratic concentration pat- 
tem, for which individual enteral reasons are suggested. When we assume 
that the absorption is relatively rapid and complete and that the half-life of 
the compound is large compared to the dosage interval and thus k0 =  Q/At 
then eq. 9 can be rewritten as the equation given by W agner et al. (1965) 
and by van  R o ssu m  and  Tomey (1968):
Q i =  1.44 Q - t j / A t . V  (13)
since 1/k =  1.44 t^
where Q  is the dose, A  t is the dosage interval and where C pi is the average 
plasma plateau concentration. This equation allows the calculation of the 
apparent distribution volume (V) of the subjects. The relative large indivi­
dual differences have been reported in table 1.
A s a consequence of the accumulation and addition of the metabolite, a 
higher concentration of the active substances in the brain and a longer time 
course of action are anticipated after subchronic treatment. However, clinical 
observation does not reveal an extension of the activity compared with the 
single dose treatment. Defined pharmacological criteria are necessary to 
allow a conclusion to this.
This brings up the second question initially mentioned in this discussion 
about the relevance of a regional drug concentration for the pharmacological 
activity.
Earlier experiments in mice have demonstrated that diazepam is exten- 
sively and rapidly taken up in the brain and in the bodyfat and that meta- 
bolites of this drug are also rapidly appearing in the stomach contents, the 
bile and subsequently in the gastrointestinal tract after intravenous injection 
(van  der  K leun  1969a).
It is very likely that this enterohepatic and to a smaller extend entero- 
gastric and enteroglandular cycling of e.g. the salivary glands and lachrymal 
glands and subsequent sustained reabsorption contribute to the erratic and
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extended concentration course of diazepam and likely other weakly basic 
compounds.
After an initial high uptake in the gray matter of the brain the drug and 
metabolites are rapidly redistributed into the fiber tracts of spinal cord, brain 
stem and the white matter of the cortex.
The gray matter of the limbic system has been recognized neurophysiolo- 
gically as the site of action of diazepam and related antianxiety drugs (S ch a l-  
l e k  et al. 1964).
It is not clear yet whether the presence in the white matter has any signifi-
d  i’a re p a m
Fig. 10. Schematic representation of the metabolic pathways of diazepam. The 
abbreviations are explained under Mèthods.
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Table 2 .
The columns 1, 2 and 3 refer to the different phases of the concentration-time curves. 
Biological half-lives of diazepam and desmethyldiazepam in different species
Species
D DD D-14C2 D-N1-WCH3
1  2 3 3 2 3 1 2  3
Mouse 4J min. 40 min. > 4  hrs > 4  hrs




* Data from v a n  d e r  K le i jn  (1969a) derived from the heart tissue concentrations.
cance for the different shades in pharmacological activity and time course of 
action. The longest retention of the radioactivity in mice is observed in the 
liver, gastrointestinal tract, bone marrow, skin and salivary and lachrymal 
glands (fig. 3).
The metabolism of diazepam has been found possibly to occur along the 
scheme given in fig. 8 (Schwartz et al. 1965; Schwartz et al. 1967). Oxy- 
diazepam and oxazepam however are only uncommonly found in human 
plasma.
The studies in dogs and mice using radio labelled drug indicate that other 
metabolites that have not been assayed by the gas chromatographic method 
must be present (fig. 1, van der Kleun 1969c). So far no qualitative and 
quantitative data on the chemical or pharmacological nature of these com- 
pounds in men are present.
Theoretically the D  OD -> O -► O-glucuronide pathway could be very 
rapid. The step from D D  to O could be rate limiting and thus be responsible 
for the accumulation of DD in plasma. A  definitive answer to this problem 
again can only be given by studies with these metabolites given as parent 
compound to the same subjects.
The differences and similarities in the kinetics reflecting mixing Wjdistribu- 
tion (2) and elimination W of drug and metabolite in three species are shown 
in table 2.
The extremely slow elimination of the total radioactivity originating from 
D-N i-14CH3 in the dog and the increasing protein binding capacity as can be 
concluded from the different slopes of the curves for plasma and plasma 
water indicates that the arisen -  14CHg -  group is taken up by the plasma 
proteins to a large extend.
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Plasma protein binding has been demonstrated to influence the pharmaco- 
kinetics of elimination for those drugs where it potentially Controls the gra­
diënt over membranes (Anton 1961). However, for the more lipophylic 
compounds that rapidly penetrate intracellularly the effect of the, by the 
binding decreased, gradiënt is effectively compensated (van der Kleun 
1969b).
Summary
Distribution in mice shows that diazepam is rapidly taken up in the brain, but 
that it is also rapidly eliminated there and slower from the body fat. Reten- 
tion of radioactivity can be observed in the gastrointestinal tract and the 
excretory organs. The studies in dogs show that the drug is also rapidly meta- 
bolized resulting in identified and unidentified metabolites some of them 
having a longer biological half-life.
Blood plasma concentrations of drug and metabolite have been followed 
during single dose, subchronic and post subchronic treatment with diazepam 
in psychiatrie patients. The accumulation of metabolites in the gastrointes­
tinal tract as observed in animal studies after intravenous administration is 
suggested to influence the kinetics of absorption and reabsorption together 
with environmental factors.
A c k n o w l e d g e m e n t s
This study has been supported by the Dutch Organization for Purely Scien- 
tific Research and the Dr. Saai van Zwanenberg Foundation. The authors 
acknowledge the cooperation of Drs. G. P. J. A . van Lier, Psychiatrie Center 
“St. Servatius” , Venray, and G. C. de Ruyter de Wildt, Psychiatrie Hospital 
“Brinkgreven” , Deventer, the Netherlands, who conducted the clinical stu­
dies. Dr. H. Kaegi of Hoffmann-La Roche Inc., Nutley, N. J., U.S.A. is 
thanked for the supply of the diazepam -  N i- 14CH3.
R EFER E N C ES
Anton, A. H.: A  drug induced change in the distribution and renal excretion of sulfo- 
namides. J. Pharmacol. 1961, 134, 291-303.
Ariëns, E. J., A. M. Simonis & J. M. van Rossum: Molecular pharmacology. Ed.: E. J.
Ariëns. Academie Press, New York and London, 1964,1, 119.
De Silva, J. A. F., B. A. Koechlin & G. Bader: Bloodlevel distribution pattems of 
diazepam and its major metabolite in man. J. Pharm. Sci. 1966, 55, 692-702. 
Doluisio, J. T. & L. W. Dittert: Influence of repetitive dosing of tetracyclines on bio­
logie half-life in serum. Clin. Pharmacol. Therap. 1969, 10, 690-701.
Gibaldi, M.: Estimation of the phannacokinetic parameters of the two-compartment 
open model from post infusion plasma concentration data. J. Pharm. Sci. 1969, 58, 
1133-1135.
PH ARM ACOKINETICS OF D IAZEPAM 127
Jelliffe, R. W.: A mathematical analysis of digitalis kinetics in patients with normal and 
reduced renal function. Math. Biosci. 1967, 1, 305-325.
Krüger Thiemer, E. & P. Bünger: The role of the therapeutic regimen in dosage design 
(part I and II). Chemotherapia 1965,10, 61-73.
Krüger Thiemer, E. & P. Bünger: The role of the therapeutic regimen in dosage design 
part I and II). Chemotherapia 1966, 10, 129-144.
Loo, J. C. K. &  S. Riegelman: Assessment of pharmacokinetic constants from post in­
fusion blood curves obtained after i.v. infusion. J. Pharm. Sci. 1970, 59, 53-55.
Marcucci, F., A. Guaitani, J. Kvetina, E. Mussini & S. Garatinni: Species differences in 
diazepam metabolism and anticonvulsant effect. Eur. J. Pharmacol. 1968, 4, 
467-470.
Marcucci, F., R. Fanelli & E. Mussini: A method for gaschromatographic determination 
of benzodiazepines. J. Chromatogr. 1968, 37, 318-320.
Randall, L. O., C. L. Scheckel & R. F. Banzinger: Pharmacology of the metabolites of 
chlordiazepoxide and diazepam. Curr. Therap. Res. 1965, 7, 590-606.
Resigno, A. & G. Serge: Drug and tracer kinetics. Blaisdell, New York, N.Y., 1966, 
29-40.
Schallek, W., F. Zabransky & A. Kuehn: Effect of benzodiazepines on central nervous 
system of cat. Arch. Int. Pharmacodyn. 1964, 149, 467-483.
Schwartz, M. A., B. A. Koechlin, E. Postma, S. Palmer &  G. Krol: Metabolism of 
diazepam in rat, dog and man. J. Pharmacol. 1965, 149, 423-435.
Schwartz, M. A., P. Bommer & F. M. Vane: Diazepam metabolites in the rat, Arch. 
Biochem. Biophys. 1967, 121, 508-516.
Ullberg, S.: Studies on the distribution an fate of S35-labeled benzylpenicillin in the 
body. Acta Radiol. 1954, suppl. 118, 22-31.
Van der Kleijn, E.: Kinetics of distribution and metabolism of diazepam and chlor­
diazepoxide in mice. Arch. Int. Pharmacodyn. 1969a, 178, 193-215.
Van der Kleijn, E.: Protein binding and lipophylic nature of ataractics of the meproba- 
mate- and diazepine group. Arch. Int. Pharmacodyn. 1969b, 179, 225-250.
Van der Kleijn, E.: Pharmacokinetics of ataractic drugs. Thesis University of Nijmegen, 
Ste Catharina Press, Bruges, Belgium, 1969c.
Van Rossum, J. M. & A. H. M. Tomey: Rate of accumulation and plateau concentra­
tion of drug after chronic medication. J. Pharm. Pharmacol. 1968, 20, 390-392.
Wagner, J. G., J. I. Northam, C. D. Alway & O. S. Carpenter: Bloodlevels of drug at 
the equilibrium state after multiple dosing. Nature 1965, 207, 1301-1302.
Wagner, J. G.: Pharmacokinetics. J. M. Richards, Publisher, Grosse Point Park, Michi- 
gan, 1969.
